Latham & Watkins Advises Itamar Medical in Acquisition by ZOLL Medical

A multidisciplinary deal team is advising the Israel-based medical technology company.

September 13, 2021

Itamar™ Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, and ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, have announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately US$538 million.

Latham & Watkins LLP represents Itamar Medical in the transaction with a corporate deal team led by Boston partner Hans Brigham and Chicago partner Max Schleusener, with associate Ariel Cho. Advice was also provided on capital markets matters by New York partner Nathan Ajiashvili, London partner Joshua Kiernan, and New York counsel Michael Rosenberg; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang; on intellectual property matters by Bay Area partner Judith Hasko, with associate Jiqiang Lin; on tax matters by New York partner Elena Romanova, with associate Shruti Hazra; on benefits and compensation matters by Washington, D.C. partner Matthew Conway, with associate Ashlie Lawton; on antitrust matters by Brussels partner Hector Armengod, Washington, D.C. partner Ian Conner, and Washington, D.C. counsel Patrick English; on CFIUS matters by Washington, D.C. partner Damara Chambers; and on data privacy and security matters by Bay Area counsel Heather Deixler.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.